Oteseconazole

(Vivjoa®)

Vivjoa®

Drug updated on 11/16/2023

Dosage FormCapsule (oral; 150 mg)
Drug ClassAzole antifungals
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential.

Product Monograph / Prescribing Information

Document TitleYearSource
Vivjoa (oteseconazole) Prescribing Information. 2022Mycovia Pharmaceuticals, Inc. Durham, NC

Systematic Reviews / Meta-Analyses